Technology
Health
Biotechnology

Rubius Therapeutics

$16.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.13 (-6.48%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RUBY and other stocks, options, ETFs, and crypto commission-free!

About

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.

Employees
65
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
1.38B
Price-Earnings Ratio
Dividend Yield
Average Volume
271.02K
High Today
$17.50
Low Today
$15.87
Open Price
$17.50
Volume
167.00K
52 Week High
$33.01
52 Week Low
$12.71

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2018 IPO
US
North America

Earnings

-$3.33
-$2.32
-$1.32
-$0.31
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.42 per share
Actual
Available Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.